Holen Sie sich die Stockscreener-App
0.4944
28.62%
0.11
Handel nachbörslich:
.50
0.0056
+1.13%
Schlusskurs vom Vortag:
$0.3844
Offen:
$0.3831
24-Stunden-Volumen:
42.20M
Relative Volume:
4.08
Marktkapitalisierung:
$78.67M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-29.47M
KGV:
-2.472
EPS:
-0.2
Netto-Cashflow:
$-21.55M
1W Leistung:
-3.13%
1M Leistung:
-77.32%
6M Leistung:
-83.18%
1J Leistung:
-86.85%
1-Tages-Spanne:
$0.3825
$0.498
1-Wochen-Bereich:
$0.3511
$0.59
52-Wochen-Spanne:
$0.20
$3.755
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Firmenname
Mereo Biopharma Group Plc Adr
Sektor
Branche
Telefon
4403330237300
Adresse
ONE CAVENDISH PLACE, LONDON
Vergleichen Sie MREO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.4944 | 61.17M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-30 | Herabstufung | Jefferies | Buy → Hold |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-13 | Fortgesetzt | BTIG Research | Buy |
| 2022-08-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Needham | Buy |
Alle ansehen
Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - Chartmill
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Sahm
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Silver Tumbles 8%; Society Pass Shares Spike Higher - Sahm
Dow Falls Over 100 Points; US Pending Home Sales Rise In November - Sahm
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta - Investing News Network
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows - Sahm
Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - Defense World
Mereo BioPharma Group’s (MREO) “Buy” Rating Reaffirmed at BTIG Research - Defense World
BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data - Investing.com UK
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
683 Capital Management LLC Decreases Stock Holdings in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat
Investors Buy High Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat
It makes sense and dollars to buy Mereo Biopharma Group Plc ADR (MREO) stock - setenews.com
Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com UK
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc (MREO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Equities Analysts Issue Forecasts for MREO FY2025 Earnings - Defense World
A better buy-in window may exist right now for Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street analysts’ outlook for Mereo Biopharma Group Plc ADR (MREO) - Setenews
FY2025 EPS Forecast for Mereo BioPharma Group Cut by Analyst - Defense World
Leerink Partnrs Has Negative Forecast for MREO Q4 Earnings - MarketBeat
Leerink Partnrs Issues Negative Forecast for MREO Earnings - Defense World
A new trading data show Mereo Biopharma Group Plc ADR (MREO) is showing positive returns. - setenews.com
[8-K] Mereo BioPharma Group plc Reports Material Event | MREO SEC FilingForm 8-K - Stock Titan
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights - Investing News Network
Mereo Biopharma Group Plc ADR (MREO) looking to reclaim success with recent performance - Setenews
Tangible book value per share of Mereo BioPharma Group plc Sponsored ADR – HAN:MAH0 - TradingView
Aberdeen Group plc Has $8.21 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
An analyst sees good growth prospects for Chime Financial Inc (CHYM) - Setenews
Finanzdaten der Mereo Biopharma Group Plc Adr-Aktie (MREO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):